Navigation Links
Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease
Date:5/27/2009

-- Longer term follow-up indicates modest efficacy in primary and related endpoints --

SAN DIEGO, May 27 /PRNewswire/ -- Ceregene, Inc. today reported additional clinical data from a double-blind, controlled Phase 2 trial of CERE-120 in 58 patients with advanced Parkinson's disease. CERE-120 uses AAV-based gene therapy to deliver the neurotrophic factor, neurturin, to Parkinson's disease patients in order to restore the function and protect degenerating nigrostriatal neurons. The company previously announced that the Phase 2 trial did not meet its primary endpoint of improvement in the Unified Parkinson's Disease Rating Scale (UPDRS) motor off score at 12 months of follow-up, although several secondary endpoints suggested a modest clinical benefit.

The additional, protocol-prescribed analyses reported today focused on further analyses of the data from the 30 subjects who continued to be evaluated under double-blind conditions for up to 18 months which indicate increasing effects of CERE-120 over time. A clinically modest but statistically significant treatment effect in the primary efficacy measure (UPDRS motor off; p=0.025), as well as similar effects on several more secondary motor measures (p<0.05), were seen at the 18 month endpoint. Not a single measure similarly favored sham surgery at either the 12 month or 18 month time points. Additionally, CERE-120 appears safe when administered to advanced Parkinson's disease patients, with no significant concerns related to the neurosurgical procedure, the gene therapy vector, or the expression of neurturin in the Parkinson's disease brain.

The company also reported the results of analyses of neurturin gene expression in the brains from two CERE-120 treated subjects who died of causes unrelated to treatment. These analyses revealed that CERE-120 produced clear evidence of neurturin expression in the targeted
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Ceregene Phase 2 Clinical Trial for Alzheimers Disease to be Funded by $5.4 Million Grant From National Institutes of Health
2. Ceregene Completes Enrollment of Phase 2 Clinical Trial for Parkinsons Disease
3. Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association
4. NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference
5. Trius Presents New Data on Torezolid Antibiotic for Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
6. Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
7. The EntreTech Forum Presents ... PHOTONICS/OPTICS - Understanding the Latest Applications of Light-based Technologies in Medical, Consumer, Industrial, and Defense Sectors
8. Chief Technology Officer for Baxa Corporations Subsidiary, FHT, Inc., Presents at the Fourth Annual unSUMMIT for Bedside Barcoding in Tampa, Florida
9. Dr. Gunther von Hagens HUMAN SAGA Project Presents Sexuality and Reproduction in New Exhibit, The Cycle of Life.
10. Americans United for Life Represents 28 Bipartisan Montana Legislators Arguing Assisted Suicide Not a Right
11. American Transplant Congress 2009: New Investigator Forum Presents Cutting Edge Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... LINCOLN, R.I. (PRWEB) September 16, 2014 ... from Sunday, Sept. 14, through Saturday, Sept. 20, ... make sure children are safe and secure while in ... from the National Traffic Highway Safety Administration (NHTSA), ... did not read the instruction manual when installing child ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Regulatory ... available regulatory information, has become a crucial skill ... device and biotechnology sectors. Regulatory Intelligence 101 ... Society (RAPS) serves as an essential guide ... Regulatory Intelligence 101 examines available regulatory intelligence tools, ...
(Date:9/16/2014)... (HealthDay News) -- Illegal drug use among teens in the ... federal report. Encouragingly, the new study also found ... products among young people between the ages of 12 and ... survey of 70,000 people aged 12 and older across the ... or abuse problems among this age group also dropped from ...
(Date:9/16/2014)... San Francisco, September 15, 2014Patients with inoperable, early-stage ... (SBRT) have a five-year survival rate of 40 ... American Society for Radiation Oncology,s (ASTRO,s) 56th Annual ... considering that historically conventional RT resulted in poor ... This study is an update of RTOG 0236, ...
(Date:9/16/2014)... of researchers at Boston University and Stanford University School ... the motion patterns of bacteria in real time and ... a bacterial colony. , The researchers chemically attached colonies ... a microscopic beam anchored at one end, similar ... to that of the bacteria. As the cantilever itself ...
Breaking Medicine News(10 mins):Health News:Amica Offers Tips During Child Passenger Safety Week 2Health News:RAPS Publishes Regulatory Intelligence 101 Book 2Health News:Fewer U.S. Teens Using Illegal Drugs and Alcohol, Report Finds 2Health News:Long-term results of RTOG 0236 confirm good primary tumor control, positive 5-year survival rates 2Health News:Long-term results of RTOG 0236 confirm good primary tumor control, positive 5-year survival rates 3Health News:And so they beat on, flagella against the cantilever 2
... kinesin CENP-E (GSK923295A) demonstrates a novel mechanism of inhibiting ... panel of human tumor cell lines in vitro: Abstract ... designed to inhibit a single protein that functions only ... range of cancer cell lines, say researchers from GlaxoSmithKline. ...
... Pharmaceuticals, a New,Jersey-based developer, manufacturer and distributor ... API and finished,dosages development and manufacturing company ... to develop, manufacture, market and distribute,several products ... product pipeline,will include at least ten ophthalmic ...
... Members of Congress Call Today for a "Medicare-Operated" ... adults and persons,with disabilities should have the option ... program to eliminate the consumer,exploitation that plagues the ... insurance companies, concludes Consumers Union and the Medicare,Rights ...
... Standards Panel (HITSP) has identified a set of,standards ... medical,information secure in an electronic environment. The standards ... only be used by authorized,personnel for official purposes., ... and privacy architecture is,the latest in a series ...
... medical care, researchers suggest , , TUESDAY, Oct. 23 (HealthDay News) ... remained constant since 2000, with some one-third of all Americans ... , But less than 25 percent of those at high ... sex or are intravenous drug users -- have been tested ...
... Affordable Treatments for the World,s ... episode of the Charlie Rose Science Series will ... -- ranging from the AIDS crisis to malaria, ... neglected diseases. A group of experts ...
Cached Medicine News:Health News:Experimental cancer pharmaceuticals under trial 2Health News:Amneal Pharmaceuticals & Indoco Remedies Finalize Long Term Joint Venture Agreement to Develop and Market Generic Ophthalmic Pharmaceuticals 2Health News:Amneal Pharmaceuticals & Indoco Remedies Finalize Long Term Joint Venture Agreement to Develop and Market Generic Ophthalmic Pharmaceuticals 3Health News:Report: Medicare-Administered Drug Benefit Would be More Affordable, Comprehensive, Stable than Current Private Insurance-Run Drug Benefit 2Health News:Report: Medicare-Administered Drug Benefit Would be More Affordable, Comprehensive, Stable than Current Private Insurance-Run Drug Benefit 3Health News:HITSP Defines Overarching Set of Healthcare Security and Privacy Standards 2Health News:Many at Risk for HIV Not Being Tested 2Health News:Many at Risk for HIV Not Being Tested 3Health News:Charlie Rose Science Series Episode #10 - GLOBAL HEALTH October 29, 2007 2
(Date:9/16/2014)... -- This report analyzes the worldwide markets for Foot Care ... Medication. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2013 ... these markets. Market data and analytics are derived from primary ...
(Date:9/16/2014)... , Sept. 16, 2014 Research and Markets ... Vaccines Market 2014-2018" report to their offering. ... immunity of animals. Animal vaccines are generally prepared from weakened ... in their healthy state. Some of the animal vaccines are ... as protein subunits or toxic components. These ...
(Date:9/16/2014)... Sept. 16, 2014 Adaptive Biotechnologies, a clinical ... to profile the adaptive immune system, is pleased to ... Chief Commercial Officer (CCO). The addition of Brain to ... hires from leading global healthcare companies, including Dean ... Counsel) from Genomic Health and Sean Nolan ...
Breaking Medicine Technology:Global Foot Care Products Industry 2Global Foot Care Products Industry 3Global Foot Care Products Industry 4Global Foot Care Products Industry 5Global Foot Care Products Industry 6Global Foot Care Products Industry 7Global Foot Care Products Industry 8Global Foot Care Products Industry 9Global Foot Care Products Industry 10Global Foot Care Products Industry 11Global Foot Care Products Industry 12Global Foot Care Products Industry 13Global Foot Care Products Industry 14Global Foot Care Products Industry 15Global Foot Care Products Industry 16Global Foot Care Products Industry 17Global Foot Care Products Industry 18Global Foot Care Products Industry 19Global Foot Care Products Industry 20Global Foot Care Products Industry 21Global Foot Care Products Industry 22Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 2Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 3Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 3
... N.J., May 24, 2012 Watson Pharmaceuticals, Inc. ... its subsidiary, Watson Laboratories, Inc., filed an Abbreviated ... and Drug Administration (FDA) seeking approval to market ... is a generic version of Auxilium Pharmaceuticals, Inc.,s ...
... ANTONIO, May 24, 2012 /PRNewswire-iReach/ -- An ... Life Science Venture Forum in Houston, Texas named TransCU ... of ten Most Promising Life Science Technologies .  ... and innovations to hundreds of early-stage investors, venture capitalists, ...
Cached Medicine Technology:Watson Confirms Testim® Patent Challenge 2Watson Confirms Testim® Patent Challenge 3New Chronic Wound Therapy Awarded at Texas' Largest Life Science Event 2
... KIMBERLY-CLARK CLOtest Rapid Urease Test is ... Standard among urease tests because of its ... by Barry Marshall, MD. who, along with ... discover the correlation between H. pylori and ...
... Rapid Test Strip and Device are rapid ... antibodies to Helicobacter pylori (H. pylori) in ... in the diagnosis of H. pylori infection ... older. They are intended for health professionals ...
... pylori WB test is a ... detection of lgG antibodies specific ... whole blood. This test kit ... in the diagnosis of H.pylori ...
... based on a lateral flow chromatography ... the qualitative detection of Helicobacter pylori ... Platinum HpSA, a microtiter assay from ... accepted as an accurate tool for ...
Medicine Products: